This company has been marked as potentially delisted and may not be actively trading. Oasmia Pharmaceutical AB (publ) (OASM) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock OASM vs. CPHI, NRBO, GRAY, AEZS, VAXX, SPRB, OGEN, ORGS, ATXI, and CANFShould you be buying Oasmia Pharmaceutical AB (publ) stock or one of its competitors? The main competitors of Oasmia Pharmaceutical AB (publ) include China Pharma (CPHI), NeuroBo Pharmaceuticals (NRBO), Graybug Vision (GRAY), Aeterna Zentaris (AEZS), Vaxxinity (VAXX), Spruce Biosciences (SPRB), Oragenics (OGEN), Orgenesis (ORGS), Avenue Therapeutics (ATXI), and Can-Fite BioPharma (CANF). These companies are all part of the "medical" sector. Oasmia Pharmaceutical AB (publ) vs. Its Competitors China Pharma NeuroBo Pharmaceuticals Graybug Vision Aeterna Zentaris Vaxxinity Spruce Biosciences Oragenics Orgenesis Avenue Therapeutics Can-Fite BioPharma China Pharma (NYSE:CPHI) and Oasmia Pharmaceutical AB (publ) (NASDAQ:OASM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment. Which has higher valuation & earnings, CPHI or OASM? China Pharma has higher revenue and earnings than Oasmia Pharmaceutical AB (publ). CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChina Pharma$4.40M1.35-$3.08MN/AN/AOasmia Pharmaceutical AB (publ)$220K6.82-$18.95MN/AN/A Does the media prefer CPHI or OASM? In the previous week, China Pharma's average media sentiment score of 0.00 equaled Oasmia Pharmaceutical AB (publ)'saverage media sentiment score. Company Overall Sentiment China Pharma Neutral Oasmia Pharmaceutical AB (publ) Neutral Do institutionals and insiders have more ownership in CPHI or OASM? 0.1% of Oasmia Pharmaceutical AB (publ) shares are held by institutional investors. 17.3% of China Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk and volatility, CPHI or OASM? China Pharma has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Oasmia Pharmaceutical AB (publ) has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Is CPHI or OASM more profitable? China Pharma has a net margin of -85.56% compared to Oasmia Pharmaceutical AB (publ)'s net margin of -8,633.64%. Oasmia Pharmaceutical AB (publ)'s return on equity of -43.94% beat China Pharma's return on equity.Company Net Margins Return on Equity Return on Assets China Pharma-85.56% -63.93% -31.42% Oasmia Pharmaceutical AB (publ) -8,633.64%-43.94%-28.92% SummaryOasmia Pharmaceutical AB (publ) beats China Pharma on 5 of the 9 factors compared between the two stocks. Get Oasmia Pharmaceutical AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for OASM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OASM vs. The Competition Export to ExcelMetricOasmia Pharmaceutical AB (publ)Pharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.50M$736.37M$5.84B$10.14BDividend YieldN/A4.84%5.68%4.60%P/E RatioN/A1.1775.4125.98Price / Sales6.8226.64515.81181.13Price / CashN/A19.5637.5660.44Price / Book0.036.6812.156.29Net Income-$18.95M-$4.13M$3.29B$271.07M Oasmia Pharmaceutical AB (publ) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OASMOasmia Pharmaceutical AB (publ)N/A$0.02flatN/AN/A$1.50M$220K0.0057CPHIChina PharmaN/A$1.84+0.5%N/A-92.1%$5.94M$4.40M0.00250News CoverageNRBONeuroBo PharmaceuticalsN/A$0.68+0.1%N/A-80.7%$5.85MN/A0.0010GRAYGraybug VisionN/A$3.58+15.9%N/A-23.8%$5.62MN/A-2.0727High Trading VolumeAEZSAeterna ZentarisN/A$3.08+1.3%N/A-23.6%$5.52M$2.37M-0.2120VAXXVaxxinityN/A$0.04+115.0%N/A-95.0%$5.45MN/A-0.1090Gap UpSPRBSpruce Biosciences1.8679 of 5 stars$8.55-11.9%$131.25+1,435.1%-64.5%$4.81M$4.91M-9.1020Gap DownOGENOragenics0.106 of 5 stars$1.15+0.9%N/A-92.4%$4.73MN/A-0.165Short Interest ↑Gap DownORGSOrgenesisN/A$0.95+850.0%N/AN/A$4.56M$662K0.00150Gap UpATXIAvenue Therapeutics1.2131 of 5 stars$0.86-3.3%N/A-70.8%$2.74MN/A0.054Gap DownCANFCan-Fite BioPharma1.9037 of 5 stars$0.66+1.1%$14.50+2,087.0%-72.4%$2.35M$560K-0.378Short Interest ↑ Related Companies and Tools Related Companies CPHI Competitors NRBO Competitors GRAY Competitors AEZS Competitors VAXX Competitors SPRB Competitors OGEN Competitors ORGS Competitors ATXI Competitors CANF Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OASM) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina’s message to TrumpDid China just fire shots at America? Last week, in Tiananmen Square, China put on a chilling display of mi...Porter & Company | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oasmia Pharmaceutical AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Oasmia Pharmaceutical AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OASM Stock Alerts